ImmunityBio, Inc. IBRX

https://www.youtube.com/shorts/_lcoCk-m74U???

$IBRX if we get fast track on QUILT 3.055 and approval on QULT 2.023, the share price would easily surge above 20.

$IBRX QUILT 3.055 is 2-3rd line with phase 2 trail with enroll only total 86 patients, that's correct. But if 2-3rd line can almost double the mOS, then the 1st line treatment phase 3 trial QUILT 2.023 which enrolled over 1500 NACLC patients RCT study would has very high chance to get positive result. The primary completion date is Oct. 2025. Do your own DD.

$IBRX "QUILT2.023"

$IBRX QUILT3.055 is about 2nd to 3rd line treatment for NSCLC. It's only at phase 2b but may able to get fast track from FDA. QUILT2.203 is first line treatment for NSCLC and it's already in phase 3. You can't predict the timing of FDA fast track agreement from FDA nor the final positive result from phase 3 trial. All you can do is buy at this reasonable share price as much as you can and hold it long. Do your own DD.

$IBRX if we get fast track for 2-3rd line NSCLC, SP go above 10 in 1 day. You just can't predict the time. All you have to do is buying and holding.

$IBRX Qulit 3.055 NACLC cohort 1a study is strong. Believe in science, stay long and be patient. PD1 is not allowed to use in 2 nd or 3rd line NSCLC patient. PD1 Plus Anktiva will be the breakthrough for MERCK this market.

$IBRX you can stop losses right now, but you may miss what happened to $SMMT. Do your own DD.

$IBRX For lung, you don't need another 5 years. QULIT 2.023, a phase 3 RCT clinical trials enrolled 1538 patients with stage 3-4 NSCLC, will have primary completion in October 2025.

$IBRX Don't expect too much in Q2 since Anktiva get approved in April. But Q3 will be interesting.